Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02476916
Recruitment Status : Active, not recruiting
First Posted : June 22, 2015
Results First Posted : June 11, 2020
Last Update Posted : August 4, 2020
Sponsor:
Information provided by (Responsible Party):
Agios Pharmaceuticals, Inc.

Brief Summary:
Study AG348-C-003 is a multicenter study designed to evaluate the safety and efficacy of different dose levels of AG-348 (mitapivat) in participants with PK deficiency.

Condition or disease Intervention/treatment Phase
Pyruvate Kinase Deficiency Drug: AG-348 Phase 2

Detailed Description:
This is a Phase 2, open label, two arm, multicenter, randomized, dose-ranging study during which adult participants with PK deficiency will receive multiple doses of AG-348 for up to 24 weeks (Core Period); eligible participants may enter an Extension Period to receive AG-348 for up to 8 additional years. Data will be reviewed on a regular basis and study design, dose and schedule will be adapted based on these reviews. The study will evaluate the safety and tolerability of multiple doses of AG-348, pharmacokinetic and pharmacodynamic (PD) profile of AG-348 and early indicators of clinical efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency
Actual Study Start Date : June 26, 2015
Actual Primary Completion Date : May 8, 2017
Estimated Study Completion Date : May 2025


Arm Intervention/treatment
Experimental: AG-348 50 mg BID
Participants with PK deficiency received AG-348, 50 milligrams (mg), as initial dose, twice daily (BID) for the Core Period (Week 24).
Drug: AG-348
Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
Other Name: Mitapivat

Experimental: AG-348 300 mg BID
Participants with PK deficiency received AG-348, 300 mg, as initial dose, BID for the Core Period (Week 24).
Drug: AG-348
Participants with PK deficiency were randomized to either receive AG-348, 50 or 300 mg, as initial doses, BID for the Core Period (Week 24). At the Week 24 visit, Core Period participants who had safely tolerated AG-348 and demonstrated clinical activity in response to AG-348 were potentially eligible to immediately roll over to the Extension Period for continued treatment. Participants were assigned to initial doses, however, over the course of the core period were treated across a range of doses due to treatment emergent adverse events (AEs) and hemoglobin (Hb) levels exceeding mid-point of sex-adjusted ranges.
Other Name: Mitapivat




Primary Outcome Measures :
  1. Percentage of Participants Experiencing at Least One Adverse Event (AEs) in the Core Period [ Time Frame: Up to Week 24 ]
    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered study drug-related.


Secondary Outcome Measures :
  1. Change From Baseline in Hemoglobin (Hb) Value at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Increased Hb values indicate improvement.

  2. Change From Baseline in Hematocrit at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Increased hematocrit values indicate improvement.

  3. Change From Baseline in Reticulocyte Count at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased reticulocyte count values indicate improvement.

  4. Change From Baseline in Haptoglobin at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Increased haptoglobin values indicate improvement.

  5. Change From Baseline in Carbon Monoxide at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased carbon monoxide values indicate improvement.

  6. Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased LDH values indicate improvement.

  7. Change From Baseline in Total Bilirubin at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased total bilirubin values indicate improvement.

  8. Change From Baseline in Indirect Bilirubin at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased indirect bilirubin values indicate improvement.

  9. Change From Baseline in Erythropoietin (EPO) at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased EPO values indicate improvement.

  10. Change From Baseline in Hepcidin at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased hepcidin values indicate improvement.

  11. Change From Baseline in Ferritin at Week 24 [ Time Frame: Baseline and Week 24 ]
    Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased ferritin values indicate improvement.

  12. Change From Baseline in Transferrin Saturation at Week 24 [ Time Frame: Baseline and Week 24 ]
    Transferrin saturation is the ratio of serum iron to iron-binding capacity. Change (absolute change) from baseline was calculated as post-baseline value - baseline value. Decreased transferrin saturation values indicate improvement.

  13. Area Under the Concentration-time Curve From Time Zero to the Last Non-zero Concentration (AUC0-t) for AG-348 and Its Metabolite AGI-8702 [ Time Frame: pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose Day 1 and pre-dose, 0.5, 1, 2, 4, 8 hours post-dose Day 15 ]
    Pre-dose pharmacokinetic concentrations, if any, were excluded from the pharmacokinetic analyses.

  14. Maximum Plasma Concentration (Cmax) for AG-348 and Its Metabolite AGI-8702 [ Time Frame: pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose Day 1 and pre-dose, 0.5, 1, 2, 4, 8 hours post-dose Day 15 ]
    Pre-dose pharmacokinetic concentrations, if any, were excluded from the pharmacokinetic analyses.

  15. Time to Reach Peak Plasma Concentration (Tmax) for AG-348 and Its Metabolite AGI-8702 [ Time Frame: pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose Day 1 and pre-dose, 0.5, 1, 2, 4, 8 hours post-dose Day 15 ]
    Pre-dose pharmacokinetic concentrations, if any, were excluded from the pharmacokinetic analyses.

  16. Apparent Clearance at Steady-State (Clss/F) for AG-348 and Its Metabolite AGI-8702 [ Time Frame: pre-dose, 0.5, 1, 2, 4, 8 hours post-dose Day 15 ]
    Pre-dose pharmacokinetic concentrations, if any, were excluded from the pharmacokinetic analyses.

  17. Maximum Change From Baseline Response Value Over 12 Hours Post-dose (BRmax) for Adenosine Triphosphate (ATP) [ Time Frame: pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose Day 1 and pre-dose, 0.5, 1, 2, 4, 8 hours post-dose Day 15 ]
    Pre-dose concentration observed on Day 1 was used as Baseline for calculation of change from baseline.

  18. Maximum Change From Baseline Response Value Over 12 Hours Post-dose (BRmax) for 2,3 - Diphosphoglycerate (2,3-DPG) [ Time Frame: pre-dose, 0.5, 1, 2, 4, 8, 12 hours post-dose Day 1 and pre-dose, 0.5, 1, 2, 4, 8 hours post-dose Day 15 ]
    Pre-dose concentration observed on Day 1 was used as Baseline for calculation of change from baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Informed consent
  2. Male or female, aged 18 years and older
  3. Known medical history of PK deficiency
  4. PK deficiency confirmed by enzymatic assay at Screening
  5. Genotypic characterization of PKR gene at Screening
  6. Genotypic characterization of uridine-5'-diphosphate-glucuronyltransferase-A1 (UGTA1) gene to document underlying Gilbert's disease (Gilbert's disease patients are eligible)
  7. Males Hb ≤ 12.0 g/dL, females Hb ≤ 11 g/dL
  8. Transfusion independent, defined as no more than 3 units of red blood cells (RBC) transfused in 12 months prior to the first day of study dosing and no transfusions within 4 months of first day of study dosing
  9. Splenectomized patients must have had the procedure at least 6 months prior to Screening and must be up-to-date in recommended vaccinations
  10. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  11. Must be taking at least 1 mg folic acid daily in the 21 days prior to screening
  12. Adequate organ function defined by liver function, kidney function, platelet count and coagulation assessments
  13. Agreement to use approved contraceptive measures
  14. Women must not be breastfeeding

    For entry into the Extension Period, patients must meet criteria # 15-16:

  15. Must have completed 24 weeks of treatment during the Core Period and tolerated AG-348
  16. The treating Investigator agrees that there is a potential for clinical benefit to continued treatment and recommends participation in the Extension Period and the Medical Monitor approves

Exclusion criteria

  1. Hb ˃ 12.0 g/dL if male, Hb ˃11.0 g/dL if female
  2. Additional diagnosis of other congenital or acquired blood disorder
  3. Iron overload sufficiently severe to result in cardiac, hepatic or pancreatic insufficiency
  4. Bone marrow or stem cell transplant
  5. Clinically symptomatic cholelithiasis or cholecystitis
  6. Currently enrolled in any other investigational trial. Participation in the PK Deficiency Natural History Study (NCT02053480) is permitted
  7. Exposure to any investigational drug, device or procedure within 28 days prior to screening or during trial participation
  8. Concurrent medical condition such as poorly controlled hypertension, heart failure, active infection, frequent post-splenectomy sepsis, Hepatitis B or C, Human Immunodeficiency Virus type 1 (HIV1) or Human Immunodeficiency Virus type 2 (HIV2) infection, poorly controlled diabetes mellitus, history of primary malignancy with the exception of curatively treated nonmelanomatous skin cancer, cervical cancer of breast cancer in situ
  9. Major surgery in the last 6 months
  10. Psychiatric disorder that could compromise the ability of the patient to cooperate with the study
  11. Serum bilirubin higher to the upper limit of normal attributable to factors other than hemolysis or Gilbert's Syndrome
  12. Use of restricted products known to strongly inhibit cytochrome P450 (CYP) 3A4 metabolism within 5 days prior to Prior Day 1 dosing, or to strongly induce cytochrome P450 3A4 (CYP3A4) metabolism within 28 days prior to Day 1 dosing, or to strongly inhibit P-glycoprotein transporter within 5 days prior to Day 1 dosing, or digoxin within 5 days prior to Day 1 dosing.
  13. Heart-rate corrected QT interval - Fridericia's method (QTcF) interval ˃ 450 ms in male, QTcF > 470 ms in female, with the exception of patients with a left Bundle Branch Block
  14. Cardiac arrhythmias that are clinically significant or treated with drugs that are substrates of CYP3A4
  15. Allergy to sulfonamides if characterized by acute hemolytic anemia, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson Syndrome
  16. Any other medical or psychological condition deemed by the Investigator to be likely to interfere with a patient's ability to participate in the study
  17. Patients will not be permitted to enter the Extension Period if: The patient experienced AEs during the Core Period that are considered by the treating Investigator or the Sponsor's designated Medical Monitor to pose a significant safety risk to the patient if treatment were to be extended

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02476916


Locations
Layout table for location information
United States, California
Stanford University
Palo Alto, California, United States, 94304
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02215
United States, Michigan
Wayne State University School of Medicine - Children's Hospital of Michigan
Detroit, Michigan, United States, 48201
United States, New York
New York Presbyterian Hospital- Weil Cornell Medical College
New York, New York, United States, 10065
United States, Pennsylvania
Central Pennsylvania Clinic
Belleville, Pennsylvania, United States, 17004
Children Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania, United States, 19104
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84113
Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2C4
France
Hôpital Henri Mondor
Créteil, Ile-de-France, France, 94010
Hôpital Saint-Vincent de Paul
Lille, Nord, France, 59000
Italy
UOC Oncoematologia Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milano, Italy, 20122
Netherlands
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands, 3584 CX
United Kingdom
Hammersmith Hospital
London, United Kingdom, W12 0NN
Sponsors and Collaborators
Agios Pharmaceuticals, Inc.
  Study Documents (Full-Text)

Documents provided by Agios Pharmaceuticals, Inc.:
Study Protocol  [PDF] June 30, 2017
Statistical Analysis Plan  [PDF] June 15, 2017

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Agios Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT02476916    
Other Study ID Numbers: AG348-C-003
2015-000484-13 ( EudraCT Number )
First Posted: June 22, 2015    Key Record Dates
Results First Posted: June 11, 2020
Last Update Posted: August 4, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Agios Pharmaceuticals, Inc.:
Pyruvate Kinase Deficiency
Hemolytic anemia
Pyruvate Kinase Isoform R (PKR)
Drive PK
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Hemolytic, Congenital Nonspherocytic
Pyruvate Metabolism, Inborn Errors
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Genetic Diseases, Inborn
Carbohydrate Metabolism, Inborn Errors
Metabolism, Inborn Errors
Metabolic Diseases